Skin penetration and metabolism of topical glucocorticoids in reconstructed epidermis and in excised human skin
- PMID: 10496654
- DOI: 10.1023/a:1018946924585
Skin penetration and metabolism of topical glucocorticoids in reconstructed epidermis and in excised human skin
Abstract
Purpose: To investigate pharmacokinetic differences between the nonhalogenated double ester prednicarbate (PC) and the fluorinated monoester betamethasone 17-valerate (BM17V) their metabolism in human keratinocytes and fibroblasts as well as their permeation and biotransformation in reconstructed epidermis and excised human skin was compared. Special attention was given to the 17-monoesters because of their high receptor affinity and antiproliferative effects.
Methods: Glucocorticoid penetration was determined using Franz diffusion cells, quantifying metabolite concentrations by HPLC. Chemical stability and reactivity of the monoesters was determined by molecular modeling analysis.
Results: PC accumulated in the stratum corneum. A considerable amount of penetrating PC was hydrolyzed by viable keratinocytes to prednisolone 17-ethylcarbonate (PI7EC), P17EC permeated the skin very rapidly when compared to BM17V. Overall P17EC concentrations in viable tissue were low. Inside of the acceptor fluid, but not within the tissue, P17EC was converted to the more stable prednisolone 21-ethylcarbonate (P21EC).
Conclusions: The inactivation of highly potent, but also cell toxic, 17-monoesters to almost inactive 21-congeners seen with isolated cell monolayers appears less important in the skin. In vitro determination of the dermal 17-monoesters concentrations may allow the prediction of the atrophogenic risk in man. BM17V levels exceeding P17EC concentration about 6-fold may contribute to its lower tolerance when compared to PC.
Similar articles
-
Prednicarbate biotransformation in human foreskin keratinocytes and fibroblasts.Pharm Res. 1997 Jun;14(6):793-7. doi: 10.1023/a:1012162708675. Pharm Res. 1997. PMID: 9210199
-
Solid lipid nanoparticles as drug carriers for topical glucocorticoids.Int J Pharm. 2000 Mar 10;196(2):165-7. doi: 10.1016/s0378-5173(99)00413-5. Int J Pharm. 2000. PMID: 10699710
-
Prednicarbate versus conventional topical glucocorticoids: pharmacodynamic characterization in vitro.Pharm Res. 1997 Dec;14(12):1744-9. doi: 10.1023/a:1012183914011. Pharm Res. 1997. PMID: 9453063
-
Topical glucocorticoids with improved risk-benefit ratio. Rationale of a new concept.Drug Saf. 1996 Jun;14(6):375-85. doi: 10.2165/00002018-199614060-00003. Drug Saf. 1996. PMID: 8828015 Review.
-
Topical glucocorticoids with improved benefit/risk ratio: do they exist?J Am Acad Dermatol. 1992 Jul;27(1):87-92. doi: 10.1016/0190-9622(92)70162-9. J Am Acad Dermatol. 1992. PMID: 1619082 Review.
Cited by
-
In Vitro Modeling of Skin Barrier Disruption and its Recovery by Ceramide-Based Formulations.AAPS PharmSciTech. 2021 Dec 14;23(1):21. doi: 10.1208/s12249-021-02154-z. AAPS PharmSciTech. 2021. PMID: 34907505
-
Systemic toxicity to betamethasone ointment.Clin Case Rep. 2020 May 25;8(9):1635-1637. doi: 10.1002/ccr3.2957. eCollection 2020 Sep. Clin Case Rep. 2020. PMID: 32983466 Free PMC article.
-
A Comparative Analysis of Biological and Synthetic Skin Models for Drug Transport Studies.Pharm Res. 2023 May;40(5):1209-1221. doi: 10.1007/s11095-023-03499-9. Epub 2023 Mar 23. Pharm Res. 2023. PMID: 36959412 Review.
-
Cyproterone acetate loading to lipid nanoparticles for topical acne treatment: particle characterisation and skin uptake.Pharm Res. 2007 May;24(5):991-1000. doi: 10.1007/s11095-006-9225-9. Epub 2007 Mar 20. Pharm Res. 2007. PMID: 17372681
-
Xenobiotic-metabolizing enzymes in the skin of rat, mouse, pig, guinea pig, man, and in human skin models.Arch Toxicol. 2014 Dec;88(12):2135-90. doi: 10.1007/s00204-014-1382-8. Epub 2014 Nov 5. Arch Toxicol. 2014. PMID: 25370008 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources